The anti-EGFR monoclonal antibody Cetuximab is approved in Europe and US for use in combination with chemo/radiation in patients with locally advanced and as monotherapy for recurrent and metastatic HNSCC [14–17]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.